Hiltonol (aka Poly-ICLC) is an immunomodulator being developed for solid tumors and other infectious diseases. By mimicking a virus, it stimulates a broad immune response, and it may have potential to boost efficacy of anticancer dendritic cell and peptide vaccines. We're keeping a close watch on several active glioma trials testing Hiltonol as a vaccine adjuvant!